June 18, 2021
Nichi-Iko Pharmaceutical said on June 17 that it has entered into a license and supply agreement with Argentina-based Laboratorio Elea Phoenix for the rights to its biosimilar version of the anti-TNFα antibody Remicade (infliximab) in Argentina. The financial specifics of...read more